Target intelligence / Profile preview

Kirsten rat sarcoma virus mRNA G-quadruplex (KRAS mRNA G4)

Target
KRAS mRNA G4
Molecular classification
Nucleic acid, RNA secondary structure, G-quadruplex, Regulatory RNA element
01

Overview

The Kirsten rat sarcoma virus mRNA G-quadruplex (KRAS mRNA G4) is a non-canonical secondary structure located within the 5'-untranslated region (5'-UTR) of the KRAS messenger RNA. This structure forms from guanine-rich sequences that fold into four-stranded arrangements stabilized by Hoogsteen hydrogen bonding (Cogoi & Xodo, 2006, Biochemistry). In its folded state, the G-quadruplex acts as a physical barrier to the 40S ribosomal subunit during scanning, effectively suppressing the translation of the KRAS protein (Cogoi et al., 2010, Journal of Medicinal Chemistry). Because KRAS is a major oncogene frequently mutated in pancreatic, colorectal, and lung cancers, this G4 structure represents a significant therapeutic target for downregulating KRAS expression at the pre-translational level (Prior et al., 2012, Cancer Research). Small molecules known as G4 ligands can bind and stabilize this structure, shifting the equilibrium toward the folded state and reducing the production of the oncogenic protein (Xodo et al., 2016, Quarterly Reviews of Biophysics). This approach is particularly valuable for targeting KRAS variants that remain difficult to inhibit with traditional protein-directed small molecules.

Other names
KRAS 5'-UTR G-quadruplexKRAS G4KRAS messenger RNA G-quadruplexKRAS G-rich sequence
02

Mechanism of action

Stabilization of the G-quadruplex structure within the 5'-untranslated region (5'-UTR) of KRAS mRNA to sterically hinder the translation machinery and inhibit protein synthesis.

03

Biological functions

Translation regulationGene expression controlmRNA stability regulation
04

Disease associations

CancerPancreatic adenocarcinomaColorectal cancerNon-small cell lung cancer
05

Safety considerations

Off-target binding to other genomic or transcriptomic G-quadruplexesPotential for systemic toxicity of G4-stabilizing ligandsInterference with global protein translationPoor bioavailability and delivery of large G4-binding molecules
06

Interacting drugs

TMPyP4

5 more in the full profile.

07

Biomarkers

KRAS mutation status (e.g., G12D, G12V, G12C)KRAS protein expression levelsG-quadruplex ligand binding affinity

Beyond the preview

Go deeper on Kirsten rat sarcoma virus mRNA G-quadruplex (KRAS mRNA G4).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kirsten rat sarcoma virus mRNA G-quadruplex (KRAS mRNA G4).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call